Sequential whole body scans with both 67Ga citrate and 111In bleomycin were performed for 14 patients undergoing staging for Hodgkin's disease or other lymphomas. A comparison of these scans gave a sensitivity in detecting the pathologically proved tumor sites of 84% for 67Ga citrate and only 56% for 111In bleomycin. In 12 patients, the gallium scan demonstrated the lesions more clearly; in the others, the uptake of the two radionuclides was equal. In no case was a clinically diagnosed or histologically proved lesion identified by 111In bleomycin that was not also demonstrated by 67Ga citrate. 111In bleomycin does not complement the 67Ga citrate scan in the scintigraphic evaluation of lymphomas.
|Original language||English (US)|
|Number of pages||8|
|State||Published - Jan 1 1977|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging